Brief: Alzamend Neuro Announces Pre-IND Submission for AL001 As Treatment of 3 Disorders
17/05/2022 13:20
May 17 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO ANNOUNCES PRE-IND SUBMISSION FOR AL001 AS A
TREATMENT OF BIPOLAR DISORDER, MAJOR DEPRESSIVE DISORDER AND
POST-TRAUMATIC STRESS DISORDER
* ALZAMEND - TOPLINE DATA EXPECTED IN DECEMBER 2022 FROM
ONGOING
PHASE IIA MULTIPLE ASCENDING DOSE CLINICAL TRIAL FOR AL001
TREATMENT OF DEMENTIA
Source text for Eikon: ID:nBw6qhf03a
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview